Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer.

ABSTRACT: Advanced colorectal cancer (CRC) is characterized by a high recurrence and metastasis rate, which is the primary cause of patient mortality. Unfortunately, effective anti-cancer drugs for CRC are still lacking in clinical practice. We screened FDA-approved drugs by utilizing targeted organoid sequencing data and found that the antifungal drug itraconazole had a potential therapeutic effect on CRC tumors. However, the effect and mechanism of itraconazole on CRC tumors have not been investigated. A cell line-derived xenograft model in tumor-bearing mice was established and single-cell RNA sequencing was performed on tumor samples from four mice with or without itraconazole treatment. The proportion of cell populations and gene expression profiles was significantly different between the two g

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC11007002 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature